stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Return on invested capital
Summit Therapeutics PLC's return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −468.7% (fiscal 2021) to 26.5% (fiscal 2019); the current reading is higher than 93% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 468.69 |
| FY2021 | −468.7% | (215.12) |
| FY2020 | −253.6% | (142.40) |
| FY2019 | −111.2% | (137.68) |
| FY2019 | 26.5% | 26.51 |
| FY2018 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | 19.9% |
| ASND Ascendis Pharma A/S compare | 15.1% |
| TECH Bio-Techne Corp compare | 7.70% |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.86% |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.73% |
| BBIO BridgeBio Pharma, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC | 0.00% |
| KYMR Kymera Therapeutics, Inc. compare | −39.3% |
| PCVX Vaxcyte, Inc. compare | −57.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement